Запись из первоисточника
СущественноеЗаявка принята
Merck sacituzumab tirumotecan (sac-TMT) BLA Accepted for Priority Review in Endometrial Cancer
U.S. FDA accepted for Priority Review a Biologics License Application for sacituzumab tirumotecan based on Phase 3 TroFuse-005 data in certain patients with advanced or recurrent endometrial cancer. This advances the regulatory path for the antibody-drug conjugate.
Ключевые факты
Выдержка из источника
EX-99.1 2 tm2628203d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 - 1 - News Release Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline Sales Growth Reflects Continued Strength in Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR Financial Highlights - Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX) o KEYTRUDA/KEYTRUDA QLEX 1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830 Million o WINREVAIR Sales Were $694 Million (93% Growth; 94% Growth ex-FX) o Animal Health Sales Were $1.7 Billion (4% Growth; 3% Growth ex-FX) - GAAP EPS Was $2.04; Non-GAAP EPS Was $2.49; GAAP an
Ещё об этом активе
26 окт. 2026 г.
15:30
MRKMSD